Tirzepatide
Also known as: Mounjaro, Zepbound, LY3298176
Dual GIP and GLP-1 receptor agonist for blood-sugar control and weight management. Weekly SubQ. Approved as Mounjaro and Zepbound.
Pharmacokinetics
- Half-life
- 5 days
- Time to peak
- 24 hours
- Bioavailability
- 80%
- Onset
- 1 hours
- Dosing interval
- Weekly (7d)
Administration
- Primary routes
- SubQ
- Category
- GLP-1 Receptor Agonists
Safety Flags
- Contraindicated in MEN2 / MTC
Storage
- · Requires refrigeration (2–8°C)
- · Temperature sensitive — minimise room-temp exposure
Used in 5 outcome protocols
- Fat Loss (Lipolysis)Primary
Accelerate fat metabolism and lipolysis without affecting growth hormone levels
Safe default: 15mg · weekly · SubQ
- Blood SugarPrimary
Regulate blood glucose levels and improve glycemic control
Safe default: 10mg · weekly · SubQ
- Appetite Suppression
Reduce appetite and support weight management goals
Safe default: 15mg · weekly · SubQ
- Insulin Sensitivity
Improve cellular response to insulin and metabolic health
Safe default: 10mg · weekly · SubQ
- Cardio Health
Support cardiovascular function and vascular health
Safe default: 10mg · weekly · SubQ
Simulate Tirzepatide
Pinned.life runs a 1-compartment Bateman pharmacokinetic simulation against 38 peptides in real time. Build a stack, see serum-level curves, get warned about peak overlaps and drug-peptide interactions.